Clinical Trials Directory

Trials / Completed

CompletedNCT03494972

A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
200 (actual)
Sponsor
University of Oslo · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The aim of this study was to investigate the effect of an oxytetracycline impregnated gauze drain on the incidence of alveolar osteitis (AO) and postoperative pain during the first week after mandibular third molar surgery.

Detailed description

The study was designed as a single-blinded randomized controlled trial. Patients were randomized in two groups by a sealed envelope system: a drain group and a control group. The study population comprised patients undergoing surgical removal of one or both mandibular third molars (3M) during January 2016 until March 2017. Patients referred to our department, who fulfilled the inclusion criteria, were asked to participate in the study. Patients were prospectively included after giving written informed consent. The inclusion criteria were: age \>18 years, indication for removal of one or both 3M, ASA I-II, no need for sedatives, possession of a smartphone with internet access (to be able to register pain score and use of analgesics, see "Data collection methods and statistical analysis"), and being able to attend a postoperative examination after 1 week. Exclusion criteria were: age \<18 years, no indication for removal of 3M, ASA III or higher, pregnancy or breastfeeding, need for sedatives or systemic antibiotics, not possessing a smartphone, and not being able to attend a postoperative examination after 1 week. The National Institutes of Health's Consensus Statement (1979) and the American Association of Oral and Maxillofacial Surgeons White Paper on Third Molar Data (2007) served as guidelines when evaluating indication for 3M removal (NIH Consensus Statement 1979, AAOMS White Paper 2007). Study population (n=200) and group size (n=100) were determined through power analysis: 90% power, 5% significance level and an expected difference of up to 10% between the two groups.

Conditions

Interventions

TypeNameDescription
DRUGTetracyclin ointmentDuring 3rd molar surgery

Timeline

Start date
2016-01-02
Primary completion
2017-03-01
Completion
2018-02-01
First posted
2018-04-11
Last updated
2018-04-11

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT03494972. Inclusion in this directory is not an endorsement.